Short answer
Twist Bioscience Corp (TWST) filed an 8-K current report with the SEC on May 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 fiscal 2026 results for quarter ended March 31, 2026.
Twist Bioscience Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 fiscal 2026 results for quarter ended March 31, 2026
- Press release furnished as Exhibit 99.1 contains financial results and management commentary
- Results announcement enables investors to assess quarterly operating performance and financial condition
Item EX-99.1 · Exhibit EX-99.1
- Q2 FY26 revenue $110.7M, up 19% YoY, marking 13 consecutive quarters of sequential growth
- DSPS revenue rose 28% to $53.3M; NGS revenue increased 12% to $57.4M
- Gross margin expanded to 51.6% from 49.6%; full-year target remains above 52%
- FY26 revenue guidance raised to $442–$447M; adjusted EBITDA breakeven reiterated for Q4
- Net loss widened to $44.0M, including $7.2M litigation costs; cash, equivalents and short-term investments totaled $172M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Twist Bioscience Corp 8-K filings
Get the next TWST 8-K as it lands
Follow TWST for push alerts, or ask the research agent what this filing means.